رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT07303556 (ICDDTKZ26) لـ فشل القلب، داء السكري النوع 2، ارتفاع ضغط الدم الشرياني هي نشط (لا يقبل مشاركين جدد). اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
دراسة واحدة تطابق معايير الفلتر
عرض البطاقة
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (ICDDTKZ26) ١٢٠ شخصي
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ رادار التجارب AI مساعدتك؛ ما عليك سوى النقر على «وصف الدراسة» لعرض ومناقشة معلومات الدراسة باللغة التي اخترتها.
التجربة السريرية NCT07303556 (ICDDTKZ26) هي دراسة تدخُّلية لـفشل القلب، داء السكري النوع 2، ارتفاع ضغط الدم الشرياني وهي نشط (لا يقبل مشاركين جدد). بدأت في ١٧ جمادى الآخرة ١٤٤٦ هـ مع خطة لتجنيد ١٢٠ مشاركًا. يقودها Nazarbayev University، ومن المتوقع اكتمالها بحلول ٢١ جمادى الأولى ١٤٤٨ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٩ شعبان ١٤٤٧ هـ.
الملخص
This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1). These medicines are called incretin-based therapies and include GLP-1 receptor agonists and a newer dual therapy that targets both GIP and GLP-1 receptors. Such medications have already shown benefits in lowering blood sugar, reducing body ...عرض المزيد
وصف مفصل
Title: Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1).
Overview:
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and in Kazakhstan. The increasing prevalence of chronic conditions such as heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 dia...
عرض المزيدالعنوان الرسمي
Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs
الحالات الطبية
فشل القلبداء السكري النوع 2ارتفاع ضغط الدم الشريانيمعرّفات دراسة أخرى
- ICDDTKZ26
- BR24993023
NCT معرّف
تاريخ البدء (فعلي)
2024-12-18
آخر تحديث مُنشور
2026-01-28
تاريخ الاكتمال (المقدر)
2026-11-01
عدد المشاركين المخطط لهم
١٢٠
نوع الدراسة
تدخُّلية
المرحلة
غ/م
الحالة
نشط (لا يقبل مشاركين جدد)
الكلمات الرئيسية
Heart Failure
Diabete Type 2
Preserved Ejection Fraction
Sequencing
Diabete Type 2
Preserved Ejection Fraction
Sequencing
الغرض الأساسي
العلاج
طريقة توزيع المشاركين
غير عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
رباعي
مجموعات/التدخلات
| مجموعة المشاركين/الذراع | التدخل/العلاج |
|---|---|
تجريبيةPatients with heart failure and preserved ejection fraction (EF ≥ 45%) Participants diagnosed with chronic heart failure with preserved ejection fraction (EF ≥ 45%) who receive treatment with glucagon-like peptide-1 (GLP-1) receptor agonists | Tirzepatide (Mounjaro) Tirzepatide is a dual GIP and GLP-1 receptor agonist administered by subcutaneous injection once weekly. It is used to improve cardiac function and metabolic control in patients with chronic heart failure with preserved ejection fraction. Dosage and treatment duration are defined by the study protocol. dapagliflozin, empagliflozin, metformin Standard treatment according to current clinical guidelines for chronic heart failure, which may include ACE inhibitors, beta-blockers, diuretics, insulin or oral hypoglycemics as appropriate. |
تجريبيةPatients with chronic heart failure with preserved ejection fraction (EF ≥ 45%) and type 2 diabetes Participants diagnosed with heart failure with preserved ejection fraction (EF ≥ 45%) and type 2 diabetes mellitus who receive treatment with glucagon-like peptide-1 (GLP-1) receptor agonists | Tirzepatide (Mounjaro) Tirzepatide is a dual GIP and GLP-1 receptor agonist administered by subcutaneous injection once weekly. It is used to improve cardiac function and metabolic control in patients with chronic heart failure with preserved ejection fraction. Dosage and treatment duration are defined by the study protocol. dapagliflozin, empagliflozin, metformin Standard treatment according to current clinical guidelines for chronic heart failure, which may include ACE inhibitors, beta-blockers, diuretics, insulin or oral hypoglycemics as appropriate. |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Change in NT-proBNP levels from baseline to Week 24 | N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker of heart failure severity. A reduction in NT-proBNP reflects improved cardiac function. This outcome assesses the effect of tirzepatide on heart failure status. | Baseline to Week 24 |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Changes in clinical parameters associated with heart failure and type 2 diabetes mellitus | Change in body weight (kg) | Baseline to Week 24 |
Changes in metabolic associated with type 2 diabetes mellitus | Change in HbA1c (%) | Baseline to Week 24 |
Assessment of the Overall Condition of Patients Before and After the Study | \- Changes in clinical parameters associated with heart failure, including quality-of-life assessment using the SF-36 questionnaire for general physical and mental health and the Minnesota Living with Heart Failure Questionnaire (MLHFQ) for heart failure-specific quality of life.
This parameter will be assessed individually, twice during the study period: at baseline and at the end at week 40 of the study, to assess the overall metabolic and cardiac impact of tirzepatide in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus. | Baseline to Week 40 |
Changes clinical parameters associated with heart failure | -Change in left ventricular ejection fraction (LVEF) by echocardiography | Baseline to Week 32 |
Changes in clinical parameters associated with heart failure and type 2 diabetes mellitus | Height parameters (cm) | Baseline to Week 24 |
مساعد المشاركة
معايير الأهلية
الأعمار المؤهلة للدراسة
بالغ, كبار السن
العمر الأدنى للدراسة
18 Years
الجنس المؤهل
الكل
- Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%)
- Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5%
- Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy)
- Stable body weight (±5%) for at least 3 months prior to screening
- Body mass index (BMI) ≥ 25 kg/m²
- Possible inclusion of patients with chronic pancreatitis in remission
- Aged 18 years or older, and not older than 75 years
- Both male and female participants
- Type 1 diabetes mellitus
- Exacerbation of chronic pancreatitis
- Acute pancreatitis
- Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy
- History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying
- Acute or chronic hepatitis
- Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73 m²
- Myocardial infarction or stroke within the past 2 months
- Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative
- Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months
- Use of weight loss medications, including over-the-counter drugs, within the past 3 months
- History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorders within the past 2 years
- Healthy individuals (no cardiovascular or metabolic disease)
Nazarbayev Universityلا توجد بيانات اتصال.
1 مواقع الدراسة في 1 بلدان
Kazakhstan
PI "National Laboratory Astana", Nazarbayev University, Astana, Kazakhstan, 010000, Kazakhstan